No Data
The founder sold the controlling stake at a 30% premium. Will Shaanxi Kanghui Pharmaceutical still sell medications in the future? | Quick read of the announcement
① Kanghui Holdings transferred 22% of its shares in Shaanxi Kanghui Pharmaceutical at 24.70 yuan/share, reflecting a premium of 31.24% compared to the price before the suspension. ② The business scope of the transferee, Yuehe Zhichuang, does not include any mention related to pharmaceuticals.
Shaanxi Kanghui Pharmaceutical (603139.SH): Resuming trading from March 21.
On March 20, Gelonghui announced that Shaanxi Kanghui Pharmaceutical (603139.SH) has announced that in order to protect the interests of all investors, according to the "Stock Listing Rules of the Shanghai Stock Exchange" and the "Self-Regulation Guidelines No. 4 for Listed Companies on the Shanghai Stock Exchange - Suspension and Resumption of Trading" and other relevant regulations, after the company applied to the Shanghai Stock Exchange, the company's stocks will resume trading starting from 9:30 AM on March 21, 2025 (Friday).
Shaanxi Kanghui Pharmaceutical (603139.SH): The actual controllers will change to Li Hongming and Wang Xuefang couple.
Gelonghui reported on March 20 that Shaanxi Kanghui Pharmaceutical (603139.SH) announced that on March 20, 2025, its controlling shareholder, Kanghui Holdings, signed a "Share Transfer Agreement" with Yuehe Zhichuang. Kanghui Holdings intends to transfer 21.9736 million shares (accounting for 22% of the total shares of the listed company) to Yuehe Zhichuang at a price of 24.70 yuan per share, resulting in a total transfer price of 0.543 billion yuan. The aforementioned shares are not subject to any pledges, freezes, or other restrictions. After this equity change is completed, Kanghui Holdings will hold 14.7326 million shares of the listed company.
Optimistic Investors Push Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Shares Up 29% But Growth Is Lacking
After two trading limit increases, Shaanxi Kanghui Pharmaceutical officially announced plans for a change in control, refuting rumors of a shell acquisition by Hengchang Pharmaceutical | Quick announcement summary.
① Due to the controlling shareholder planning a share transfer, Shaanxi Kanghui Pharmaceutical Stocks have been suspended from trading since the 19th. ② Shaanxi Kanghui Pharmaceutical stated that, aside from a small collaboration with Hengchang Pharmaceutical on a Business level, there is no related cooperation in terms of backdoor listing.
Shaanxi Kanghui Pharmaceutical (603139.SH): Kanghui Holdings is planning to transfer the company's shares through an agreement. Stocks have been suspended from trading since March 19.
Gelonghui reported on March 18 that Shaanxi Kanghui Pharmaceutical (603139.SH) announced that on March 18, 2025, it received a notification from its controlling shareholder, Shaanxi Kanghui Holdings Co., Ltd. (hereinafter referred to as 'Kanghui Holdings'), that Kanghui Holdings is planning to transfer the company's shares by agreement, which may result in a change of control of the company. Upon the company's application, trading of the company's Stocks will be suspended from March 19, 2025 (Wednesday) for no more than 2 days.
Improved Revenues Required Before Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Stock's 33% Jump Looks Justified
